(4-methoxy-2-methylphenyl)methanamine | 21883-14-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-methoxy-2-methylphenyl)methanamine
• 英文别名: 4-methoxy-2-methyl-benzylamine
• CAS: 21883-14-7
• 化学式: C₉H₁₃NO
• mdl: MFCD11045200
• 分子量: 151.208
• InChiKey: RYTPCWXDKCCDBI-UHFFFAOYSA-N

物化性质

• 沸点：
  257.5±25.0 °C(Predicted)
• 密度：
  1.0386 g/cm3(Temp: 26 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险类别：
  8
• 危险性防范说明：
  P501,P264,P280,P303+P361+P353,P301+P330+P331,P363,P304+P340+P310,P305+P351+P338+P310,P405
• 危险品运输编号：
  2735
• 危险性描述：
  H314
• 包装等级：
  III

反应信息

• 作为反应物：
  描述：

  (4-methoxy-2-methylphenyl)methanamine 在 仲丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 0.17h， 生成 2-(tert-butoxycarbonyl)-3-hydroxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  杂原子导向的侧向锂化：从 N-（叔丁氧基羰基）-2-甲基苄胺合成异喹啉衍生物

  摘要：

  开发了从 N-（叔丁氧基羰基）-2-甲基苄胺 (1) 制备异喹啉衍生物的方法。1 转化为二锂物种，然后与 DMF 缩合得到 Boc-3-羟基-1,2,3,4-四氢异喹啉 3，其可以脱水为 1,2-二氢异喹啉 4。二氢化合物 4 的氢化得到相应的四氢异喹啉 5. 用 N-甲氧基-N-甲基酰胺处理来自 1 的二锂物种得到酮 14，将其转化为 3-取代的二氢异喹啉 15、四氢异喹啉 (16, 17) 或异喹啉 (20)。

  DOI：

  10.1139/v94-005
• 作为产物：
  描述：

  2-甲基-4-甲氧基苯腈 在 lithium aluminium tetrahydride 作用下， 以 乙二醇二甲醚 为溶剂， 生成 (4-methoxy-2-methylphenyl)methanamine
  参考文献：
  名称：

  8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: Selective and Centrally Active Corticotropin-Releasing Factor Receptor-1 (CRF₁) Antagonists

  摘要：

  This report describes the syntheses and structure-activity relationships of 8-(4-methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF1) receptor antagonists. CRF1 receptor antagonists may be potential anxiolytic or antidepressant drugs. This research culminated in the discovery of analogue 12-3. which is a potent, selective CRF1 antagonist (hCRF(1) IC50 = 4.7 +/- 2.0 nM) with weak affinity for the CRF-binding protein and biogenic amine receptors. This compound also has a good pharmacokinetic profile in dogs. Analogue 12-3 is orally effective in two rat models of anxiety: the defensive withdrawal (situational anxiety) model and the elevated plus maze test. Analogue 12-3 has been advanced to clinical trials.

  DOI：

  10.1021/jm9000242

文献信息

• HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20180065981A1

  公开（公告）日：2018-03-08

  The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.

  本申请涉及具有特定类型的(氮杂杂环基)甲基取代基的新型噻吩并[2,3-d]嘧啶-2,4-二酮（“噻吩尿嘧啶”）衍生物，以及其制备方法，单独或组合用于治疗和/或预防疾病，以及用于生产用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防肺部和心血管疾病以及癌症的用途。
• Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
  申请人：Tachdjian Catherine

  公开号：US20050084506A1

  公开（公告）日：2005-04-21

  The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers,—savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.

  本发明涉及发现，某些非天然存在的非肽酰胺化合物和酰胺衍生物，如草酰胺、脲和丙烯酰胺，可用作风味或口味调节剂，例如风味或调味剂和风味或口味增强剂，更具体地说，是用于食品、饮料和其他可食用或口服药品或组合物的风味或口味调节剂，包括鲜味（味精的“鲜味”）或甜味调节剂，鲜味或甜味调味剂以及鲜味或甜味增强剂。
• LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20170050964A1

  公开（公告）日：2017-02-23

  The present application describes lactam-containing compounds and derivatives thereof of Formula I: P 4 —P-M-M 4 I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  本申请描述了公式I中含有内酰胺的化合物及其衍生物：P4—P-M-M4I或其药用盐形式，其中环P（如果存在）是一个5-7成员的碳环或杂环，环M是一个5-7成员的碳环或杂环。本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶的抑制剂，特别是因子Xa。
• Compounds for the Treatment of Hepatitis C
  申请人：Bristol-Myers Squibb Company

  公开号：US20130203758A1

  公开（公告）日：2013-08-08

  The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

  该披露提供了化合物I的公式，包括药用可接受的盐，以及使用这些化合物的组合物和方法。这些化合物对丙型肝炎病毒（HCV）具有活性，并可能在治疗感染HCV的患者中有用。
• NOVEL PHENAZINE DERIVATIVES AND THEIR USES
  申请人：Feron Olivier

  公开号：US20130289030A1

  公开（公告）日：2013-10-31

  The present invention is directed to novel compounds of formula I and their use as anti-angiogenic agents and anti-cancer agents.

  本发明涉及一种新型化合物的公式I及其用作抗血管生成和抗癌剂的用途。